Christopher J. Lord

机构：Institute of Cancer Research, Breast Cancer Now · ORCID：0000-0002-3226-0515

发表论文 719 篇 · 总被引 47186 次 · h-index 99

代表论文

• NASP modulates histone turnover to drive PARP inhibitor resistance (2025 · Nature · 被引 17)
• The transcriptomic architecture of common cancers reflects synthetic lethal interactions (2025 · Nature Genetics · 被引 13)
• PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma (2025 · Oncogene · 被引 13)
• Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial (2025 · Nature Communications · 被引 12)
• Proteogenomic discovery of RB1 -defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets (2025 · Science Advances · 被引 12)
• Clinical challenges and proposed solutions for patients with invasive lobular breast cancer (2025 · Annals of Oncology · 被引 10)